Damora Therapeutics Appoints Biotechnology Leader Jennifer Jarrett as President and Chief Executive Officer; Adds Two Industry Veterans to Board of Directors
(DMRA)
Company Research
Source: GlobeNewswire
-- Ms. Jarrett brings nearly three decades of executive leadership in biotech, tech and finance -- -- Biotech leaders Dr. Cameron Turtle and Mike Landsittel appointed to Board of Directors -- -- Peter Harwin named Chairman of the Board of Directors -- BOSTON, March 23, 2026 (GLOBE NEWSWIRE) -- Damora Therapeutics, Inc. (NASDAQ: DMRA), a biotechnology company working to fundamentally redefine care for patients with blood disorders, today announced that its Board of Directors has appointed Jennifer Jarrett as President and Chief Executive Officer, effective March 30, 2026. Ms. Jarrett will also serve on the company’s Board of Directors. “We are excited to welcome Jen to Damora as we accelerate our efforts to bring innovative medicines to patients with mutant calreticulin (mutCALR)-driven myeloproliferative neoplasm (MPNs),” said Peter Harwin, Chairman of the Board of Directors of Damora Therapeutics. “With a track record of success in oncology drug development and building and lea
Show less
Read more
Impact Snapshot
Event Time:
DMRA
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
DMRA alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
DMRA alerts
High impacting news events
Weekly update
A roundup of the hottest topics
DMRA
News
- Damora Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)GlobeNewswire
- Damora Therapeutics, Inc. Common Stock (DMRA) is now covered by Evercore Inc. They set an "outperform" rating and a $46.00 price target on the stock.MarketBeat
- Damora Therapeutics Reports Full-Year 2025 Financial Results and Recent Corporate HighlightsGlobeNewswire
DMRA
Analyst Actions
- 3/25/26 - Evercore ISI Group